CClinicalTrials.gg
CompletedNCT00417339Updated May 13, 2016

Protein-bound Uremic Retention Solutes and Long Nocturnal Hemodialysis: a Longitudinal Analysis

An observational study in End Stage Kidney Disease, sponsored by Universitaire Ziekenhuizen KU Leuven. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-13.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
38
Ages
18 Years and older
Sex
All
01

Study summary

Study on intradialytic kinetics of protein-bound uremic retention solutes during long nocturnal hemodialysis

Read the detailed description

Although remarkable progress has been made, chronic kidney disease still poses a major burden on both individual patients, as well as on society as a whole. There is a strong inverse relationship between decreasing renal function, as estimated by glomerular filtration rate, and mortality rate, especially death due to cardiovascular disease. The exact cause(s) remain to be elucidated. Uremic toxins might play an important role.

In the course of decreasing renal function the concentration of numerous intracellular and extracellular compounds vary from the non-uremic state. A still increasing number of uremic retention solutes are being identified. Renal replacement strategies aim to remove potentially harmful substances from the body. Traditionally much attention has been paid to small water-soluble molecules such as urea nitrogen and creatinine. Based on the results of the recent HEMO and ADEMEX studies, increases of small water-soluble solute removal above the level reached with modern dialysis techniques (HD, PD) seem not to be advantageous with regard to patient outcome. These findings may point to the importance of other distinct groups of uremic retention solutes. In view of the data described above, protein-bound solutes might be good candidates.

Several advantages of long duration hemodialysis have been observed, including a better control of blood pressure by decreasing extracellular fluid volume, lowering peripheral vascular resistance and improving endothelium-dependent and -independent vasodilation. A normalization of heart rate variability and improvement of left-ventricular function was noted as well. Furthermore, anemia control has been shown to be easier and several nutritional parameters improved in patients treated with long duration HD. The therapy results in higher small water-soluble solute removal, phosphate removal and greater elimination of larger molecules (e.g. β2-microglobulin).

It seems an appealing question whether a better control of the serum levels of protein-bound solutes can be achieved by long duration (nocturnal) hemodialysis. This might be another advantage of this therapeutic modality, or may even in part explain the better outcome of patients treated this way.

The study compares intermittent hemodialysis with long nocturnal hemodialysis with respect to serum concentrations of several protein bound uremic toxins, as well as solute removal.

02

Conditions studied

  • End Stage Kidney Disease

Keywords

  • hemodialysis
  • dialysis adequacy
  • uremic retention solute
03

In context

Kidney Diseases

3,840 studies on the registry are indexed under Kidney Diseases; 500 are open to participants now.

This study's enrollment of 38 is below the median of 192 across 1,033 observational studies indexed under Kidney Diseases.

Browse Kidney Diseases studies →

Lead sponsor

Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 928 studies on the registry; 261 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

maintenance dialysis patients

Inclusion criteria

  • Start hemodialysis during 2007
  • Age over 18 years
  • Informed consent

Exclusion criteria

Exclusion Criteria:

  • Non consent
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
38 participants (actual)
Biospecimen retention
Samples without dna

Groups and cohorts

  • hemodialysis, 4h, twice weekly

    hemodialysis, four hours, twice weekly

    Procedure: hemodialysis

  • hemodialysis, 8h, twice weekly

    hemodialysis, eight hours, twice weekly

    Procedure: hemodialysis

  • hemodialysis, 8h, every other day

    hemodialysis, eight hours, every other day

    Procedure: hemodialysis

  • hemodialysis, 8h, six days per week

    hemodialysis, eight hours, six days per week

    Procedure: hemodialysis

Interventions

  • Procedurehemodialysis

    individualised

06

Study locations

4 sites
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • Geelong Hospital
    Geelong, Victoria 3220, Australia
  • Universitaire Ziekenhuizen Leuven
    Leuven, Brabant 3000, Belgium
  • Virga Jesseziekenhuis
    Hasselt, Limburg 3500, Belgium
07

References and documents

Publications

  • Bammens B, Evenepoel P, Keuleers H, Verbeke K, Vanrenterghem Y. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int. 2006 Mar;69(6):1081-7. doi: 10.1038/sj.ki.5000115. PubMed 16421516 ↗
  • Fagugli RM, De Smet R, Buoncristiani U, Lameire N, Vanholder R. Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. Am J Kidney Dis. 2002 Aug;40(2):339-47. doi: 10.1053/ajkd.2002.34518. PubMed 12148107 ↗
  • Pierratos A. Daily nocturnal home hemodialysis. Kidney Int. 2004 May;65(5):1975-86. doi: 10.1111/j.1523-1755.2004.00603.x. No abstract available. PubMed 15086951 ↗

Individual participant data

Plan to share: No

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 13, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00417339
Lead sponsor
Universitaire Ziekenhuizen KU Leuven
Responsible party
Björn Meijers (Prof, Universitaire Ziekenhuizen KU Leuven) — Principal investigator
First posted
Jan 1, 2007
Start date
Dec 2006
Primary completion
Dec 2014
Completion
Dec 2014
Last update
May 13, 2016

Study contacts

Björn KI Meijers, MD
principal investigator · Universitaire Ziekenhuizen KU Leuven
Pieter Evenepoel, MD, PhD
study director · Universitaire Ziekenhuizen KU Leuven
Tom Dejagere, MD
principal investigator · Virga Jesse Ziekenhuis
Nigel Toussaint, MD
principal investigator · Geelong Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion